Investor-Initiated Research Grants
The Investor-Initiated Research Grants from Beyond Batten Disease Foundation fund global research to advance understanding and treatment of juvenile Batten (CLN3) disease.
Funder: Beyond Batten Disease Foundation
Due Dates: Rolling (no deadline)
Funding Amounts: $5,000–$2,000,000 per award (average ~$150,000 over two years); highly flexible based on project scope
Summary: Supports innovative research projects advancing understanding and treatment of juvenile Batten (CLN3) disease through a collaborative, rolling submission process.
Key Information: Letter of Intent required before full proposal; open to global applicants from academia, industry, and clinical backgrounds.
Description
The Beyond Batten Disease Foundation (BBDF) offers flexible, investor-initiated research grants to accelerate the understanding, diagnosis, and treatment of juvenile Batten (CLN3) disease. BBDF encourages proposals from investigators worldwide, seeking novel approaches that align with its mission to eradicate Batten disease. The program is open to a broad range of research activities, including basic discovery, translational studies, biomarker identification, clinical endpoint development, and projects that help de-risk pharmaceutical investment or facilitate clinical trials. BBDF values collaboration and integrates input from diverse stakeholders to maximize the impact of funded projects.
